Indole acids as a novel PDE2 inhibitor chemotype that demonstrate pro-cognitive activity in multiple species

Bioorganic & Medicinal Chemistry Letters
2018.0

Abstract

An internal HTS effort identified a novel PDE2 inhibitor series that was subsequently optimized for improved PDE2 activity and off-target selectivity. The optimized lead, compound 4, improved cognitive performance in a rodent novel object recognition task as well as a non-human primate object retrieval task. In addition, co-crystallization studies of close analog of 4 in the PDE2 active site revealed unique binding interactions influencing the high PDE isoform selectivity.

Knowledge Graph

Similar Paper

Indole acids as a novel PDE2 inhibitor chemotype that demonstrate pro-cognitive activity in multiple species
Bioorganic & Medicinal Chemistry Letters 2018.0
Structure-Guided Design and Procognitive Assessment of a Potent and Selective Phosphodiesterase 2A Inhibitor
ACS Medicinal Chemistry Letters 2018.0
Novel indolizine compounds as potent inhibitors of phosphodiesterase IV (PDE4): structure–activity relationship
Med. Chem. Commun. 2010.0
Novel anilide and benzylamide derivatives of arylpiperazinylalkanoic acids as 5-HT1A/5-HT7 receptor antagonists and phosphodiesterase 4/7 inhibitors with procognitive and antidepressant activity
European Journal of Medicinal Chemistry 2020.0
Design, synthesis of novel purin-6-one derivatives as phosphodiesterase 2 (PDE2) inhibitors: The neuroprotective and anxiolytic-like effects
Bioorganic & Medicinal Chemistry Letters 2019.0
Synthesis and structure–activity relationships of 4-oxo-1-phenyl-3,4,6,7-tetrahydro-[1,4]diazepino[6,7,1- hi ]indoles: novel PDE4 inhibitors
Bioorganic & Medicinal Chemistry Letters 2000.0
Design, synthesis and biological evaluation of novel tetrahydroisoquinoline derivatives as potential PDE4 inhibitors
Bioorganic & Medicinal Chemistry Letters 2015.0
The synthesis and biological evaluation of a novel series of indole PDE4 inhibitors I
Bioorganic & Medicinal Chemistry Letters 1998.0
Design and Synthesis of Selective Phosphodiesterase 4D (PDE4D) Allosteric Inhibitors for the Treatment of Fragile X Syndrome and Other Brain Disorders
Journal of Medicinal Chemistry 2019.0
Discovery and Optimization of α-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia
Journal of Medicinal Chemistry 2020.0